On April 13,2021,the US Centers for Disease Control and Prevention(CDC)and the US Food and Drug Administration(FDA)recommended a pause in administration of the Ad26.COV2.S(Johnson&Johnson[Janssen])coronavirus dise...On April 13,2021,the US Centers for Disease Control and Prevention(CDC)and the US Food and Drug Administration(FDA)recommended a pause in administration of the Ad26.COV2.S(Johnson&Johnson[Janssen])coronavirus disease 2019(COVID-19)vaccine for all persons[1].At that time,approximately 6.8 million doses of vaccine had been administered around the United States.The pause was prompted by 6 cases of cerebral venous sinus thrombosis(CVST)in combination with thrombocytopenia,a condition whose nomenclature is in flux but which we will refer to as thrombosis with thrombocytopenia syndrome(TTS),as used by CDC in describing the condition[2].All patients were women younger than 50 years.Of note,2 of 6 patients also had splanchnic and portal vein thrombosis.展开更多
文摘On April 13,2021,the US Centers for Disease Control and Prevention(CDC)and the US Food and Drug Administration(FDA)recommended a pause in administration of the Ad26.COV2.S(Johnson&Johnson[Janssen])coronavirus disease 2019(COVID-19)vaccine for all persons[1].At that time,approximately 6.8 million doses of vaccine had been administered around the United States.The pause was prompted by 6 cases of cerebral venous sinus thrombosis(CVST)in combination with thrombocytopenia,a condition whose nomenclature is in flux but which we will refer to as thrombosis with thrombocytopenia syndrome(TTS),as used by CDC in describing the condition[2].All patients were women younger than 50 years.Of note,2 of 6 patients also had splanchnic and portal vein thrombosis.
